# US Genome Editing Engineering Market > United States Genome Editing Engineering Market Research Report Information By Technology (Mega nucleases, Cas9, TALENs/MegaTALs, ZFN, Others), By Delivery Method (Ex-vivo, In-vivo) By Mode (Contract, In-house), By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), By Application (Genetic Engineering, Clinical Applications) – United States Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.87% - **2024:** $ 403.2 Million - **2025:** $ 487.68 Million - **2035:** $ 2,700 Million - **Key Players:** Monsanto (US), DuPont (US), Syngenta (US), Bayer (US), Amgen (US), Genentech (US), Illumina (US), Regeneron Pharmaceuticals (US), Corteva Agriscience (US) **Report ID:** MRFR/HC/20201-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-genome-editing-engineering-market-21799 --- ## Market Summary ## **United States Genome Editing Engineering Market Overview** As per MRFR analysis, the United States Genome Editing Engineering Market Size was estimated at 3.12 (USD Billion) in 2023. The United States Genome Editing Engineering Market Industry is expected to grow from 3.70 (USD Billion) in 2024 to 13.69 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 15.63% during the forecast period (2024 - 2032). Expanding use of CRISPR genome editing technology across a range of scientific domains and rising demand for synthetic genes are the main market drivers anticipated to propel the United States genome editing engineering market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **United States Genome Editing Engineering Market Trends** The United States market's growth has mostly been fueled by rising demand for synthetic genes and rising use of CRISPR genome editing technology across a range of biotechnology industries. Rising government financing, a rise in the output of genetically modified crops, and an increase in the number of genomics projects are also expected to contribute to the market CAGR growth. CRISPR-based diagnostic techniques that have aided in COVID-19 diagnosis are another factor driving the growth. In March 2021, for instance, a team of researchers from Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in the United States. The diagnostics sector will employ CRISPR genome editing technology more frequently as a result of this test's capacity to detect mutant strains of SARS-CoV-2. Furthermore, the capacity of the gene-editing technology market to turn a profit is significantly influenced by ongoing technological advancements. In April 2021, for instance, researchers at Harvard's Wyss Institute for Biologically Inspired Engineering developed Retron Library Recombine ring (RLR). Editing rates increased because millions of genetic tests could be conducted simultaneously thanks to this new gene-editing technology. With more government backing and financing for scientific research and development, the United States commanded the biggest market share for genome editing technologies. It is also expected that the presence of significant players like Editas Pharmaceuticals, Thermo Fisher Scientific, and CRISPR Therapeutics, as well as rising investment in genomic research, will drive market expansion in this region Additionally, a methodology for using the CRISPR-based Specific High Sensitivity Enzymatic Reporter Unlocking (SHERLOCK) technology to identify COVID-19 has been released by researchers at the Broad Institute of MIT and Harvard. This new method detects the COVID-19 target sequences by using artificial COVID-19 virus RNA fragments. These sequences can be found in the region of 20–200 aM. Therefore, the market is expected to grow as a result of research and educational institutions' continued development of new CRISPR editing tools. ## **United States Genome Editing Engineering Market Segment Insights** The United States Genome Editing Engineering market segmentation, based on Technology, includes Meganucleases, Cas9, TALENs/MegaTALs, ZFN, and Others. The Cas9 segment dominated the market mostly. This technique is helpful for gene therapy, the creation of novel medications, and scientific study since it can precisely split DNA strands and introduce new genetic material. Because of its versatility, ease of use, high efficiency, and precision, CRISPR/Cas9 is a well-liked substitute for genome editing in a variety of contexts. The United States Genome Editing Engineering market segmentation, based on Delivery Method, includes Ex-vivo and In-vivo. Ex-vivo generated the most income. This is explained by the benefits this mode type provides, namely easy control over DNA modification. With more people using this distribution strategy, the ex-vivo delivery segment has grown as a result of the expanding clinical trial pipeline that makes use of genome processing tools. The United States Genome Editing Engineering market segmentation, based on Mode, includes Contract and In-house. The contract segment dominated the market mostly. This can be linked to the high level of outsourcing in the gene editing industry, which is motivated by the reduced expenses and more operational flexibility that these activities provide in comparison to in-house development. The segment is anticipated to continue growing. The United States Genome Editing Engineering market segmentation, based on End-use, includes Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. The biotechnology & pharmaceutical companies generated the most income. The primary cause of revenue generation is the existence of an increasing amount of research activities for the development of novel therapeutics. In addition, multinational pharmaceutical corporations are working with startup businesses to create innovative technologies. The United States Genome Editing Engineering market segmentation, based on Application, includes Genetic Engineering and Clinical Applications. The genetic engineering segment dominated the market mostly. This is because the science of stem cell and gene therapy is expanding quickly. The use of CRISPR gene editing in programs pertaining to human induced pluripotent stem cells (hiPSCs) has significant ramifications for stem cell research for the treatment of different disorders. **Figure 1: United States Genome Editing Engineering Market, by Application, 2022 & 2032 (USD Billion)** **** Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **United States Genome Editing Engineering Country Insights** Market expansion is fueled by ongoing developments in genome editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, which the United States enhances gene editing procedures' accuracy, effectiveness, and user-friendliness. Growing public awareness of genome editing's potential applications in agriculture, healthcare, and other fields encourages acceptance and implementation of these technologies, which in turn fuels demand in the market. The United States As per the deal, CRISPR Therapeutics will provide its genome editing knowledge, while Capsida will offer its adeno-associated virus (AAV) delivery technology. With the accomplishment of the Human Genome Project (HGP), around 7,000 new genetic disorders affecting humans have been identified. Although gene treatments based on ex vivo gene editing, such as CAR-T, have had a substantial impact. Moreover, in the United States, the majority of patients with hereditary illnesses need in vivo therapies. ## **United States Genome Editing Engineering Key Market Players & Competitive Insights** Leading market players are putting a lot of money into R&D to increase the range of products they sell, which will encourage further growth in the United States Genome Editing Engineering sector. Additionally, market players are engaging in a range of calculated actions to increase their presence, with important market developments including releases of new products, contracts, acquisitions and mergers, increased investments, and cooperation with other enterprises. To grow and endure in a market that is becoming more and more competitive, the United States Genome Editing Engineering industry must provide reasonably priced goods. Major players in the United States Genome Editing Engineering market are making investments in R&D operations in an effort to boost market demand, including Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis S.A., AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc. ### **Key Companies in the United States Genome Editing Engineering market include** ## **United States Genome Editing Engineering Industry Developments** **January 2022:**Pfizer, a global pharmaceutical and biotechnology company with headquarters in the United States, and Beam Therapeutics, a Massachusetts-based company that was first to create CRISPR editing tools, have agreed to a $300 million, four-year contract. **June 2021:**The biotechnology firm Regeneron Pharmaceuticals, with its headquarters located in New York, and Cambridge-based Intellia Therapeutics, which develops biopharmaceuticals, have jointly disclosed a novel therapy that specifically targets the faulty gene responsible for transthyretin amyloidosis. ## **United States Genome Editing Engineering Market Segmentation** ### **United States Genome Editing Engineering Technology Outlook** ### **United States Genome Editing Engineering Delivery Method Outlook** ### **United States Genome Editing Engineering Mode Outlook** ### **United States Genome Editing Engineering End-use Outlook** ### **United States Genome Editing Engineering Application Outlook** ## Market Drivers ### Growing Public Awareness and Acceptance Public awareness and acceptance of [genetic engineering](https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528) technologies are evolving within the US Genetic Engineering Market. Educational initiatives and outreach programs have contributed to a better understanding of the benefits and safety of genetically modified organisms (GMOs). Surveys indicate that consumer acceptance of GM foods has increased, with approximately 60% of Americans now supporting their use. This shift in public perception is crucial for the market's growth, as it encourages food manufacturers to incorporate genetically engineered ingredients into their products. As consumers become more informed, the demand for GMOs is likely to rise, further driving the market forward. ### Innovations in Gene Editing Technologies The US Genetic Engineering Market is witnessing rapid advancements in gene editing technologies, particularly CRISPR-Cas9. These innovations are revolutionizing the way genetic modifications are made, allowing for more precise and efficient alterations. The market for gene editing is projected to reach USD 5 billion by 2027, reflecting a compound annual growth rate of over 20%. This surge is attributed to the technology's potential applications in agriculture, medicine, and industrial biotechnology. As researchers and companies continue to explore the capabilities of gene editing, the US market is likely to see an influx of new products and solutions that address various challenges, from crop diseases to genetic disorders. ### Regulatory Support for Genetic Engineering The regulatory landscape for genetic engineering in the US is becoming increasingly supportive, which is a significant driver for the US Genetic Engineering Market. The USDA and FDA have established frameworks that facilitate the approval process for genetically engineered products, streamlining the path to market for new innovations. In 2025, the USDA announced a new initiative aimed at expediting the review of gene-edited crops, which could potentially reduce the time and cost associated with bringing these products to market. This regulatory support not only encourages investment in genetic engineering but also enhances the competitiveness of US products in the global market. ### Rising Demand for Genetically Modified Crops The US Genetic Engineering Market is experiencing a notable increase in demand for genetically modified (GM) crops. This trend is driven by the need for enhanced agricultural productivity and sustainability. According to the USDA, the adoption of GM crops has led to a significant reduction in pesticide use, which is appealing to environmentally conscious consumers. In 2025, approximately 94% of soybean and 92% of cotton planted in the US were genetically engineered varieties. This growing acceptance of GM crops among farmers and consumers alike is likely to propel the market forward, as stakeholders seek to address food security challenges and improve crop resilience against climate change. ### Increased Investment in Biotechnology Research Investment in biotechnology research is a critical driver of the US Genetic Engineering Market. In recent years, federal funding for genetic research has increased, with the National Institutes of Health (NIH) allocating over USD 40 billion annually for biomedical research. This financial support fosters innovation and encourages collaboration between academic institutions and private companies. Furthermore, venture capital investments in biotech startups have surged, with over USD 10 billion invested in 2025 alone. This influx of capital is likely to accelerate the development of new genetic engineering applications, enhancing the overall growth of the market and positioning the US as a leader in biotechnology. ## Future Outlook The US Genetic Engineering Market is poised for robust growth at 18.87% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for genetically modified products. **New opportunities:** - Development of precision gene editing tools for agricultural applications. - Expansion of CRISPR-based therapies in personalized medicine. - Investment in biomanufacturing facilities for scalable genetic product production. By 2035, the market is expected to achieve substantial growth, solidifying its position as a leader in biotechnology. ## Segment Insights ### By Application: Agricultural Biotechnology (Largest) vs. Medical Biotechnology (Fastest-Growing) The US Genetic Engineering Market showcases a diverse distribution across its application segments, prominently featuring Agricultural Biotechnology as the largest segment. This is driven by the significant demand for genetically modified crops, which enhance yield and resistance to pests. In contrast, Medical Biotechnology is gaining traction, capturing interest due to its potential in developing innovative therapies and diagnostic tools, resulting in rapid growth in this field. The Industrial and Environmental Biotechnology segments, while present, command smaller market shares in comparison to these two leading applications. As the market evolves, several trends and drivers are influencing growth within the Application segment. Agricultural Biotechnology continues to lead, bolstered by rising consumer demand for sustainable food sources and climate-resilient crops. Meanwhile, Medical Biotechnology is propelled by advancements in precision medicine and the increasing ability to edit genomes for therapeutic purposes. These segments are interconnected, with innovations in one area often propelling growth in the other, particularly as medical applications explore crop biotechnology to enhance food security and health outcomes. Agricultural Biotechnology (Dominant) vs. Industrial Biotechnology (Emerging) Agricultural Biotechnology stands as a dominant player within the US Genetic Engineering Market, focusing on the genetic modification of crops to improve agricultural output. This segment is characterized by its vast investment in research and development aimed at enhancing crop productivity and sustainability. In contrast, Industrial Biotechnology is emerging, leveraging biochemical processes to create sustainable products and solutions in various industries such as textiles, chemicals, and biofuels. While still in its developmental phase in the context of genetic engineering, Industrial Biotechnology is aligning with the growing corporate focus on sustainability, indicating a future potential that could redefine manufacturing processes and environmental impact. Both segments highlight the versatility and transformative power of genetic engineering in addressing contemporary challenges. ### By End Use: Pharmaceuticals (Largest) vs. Agriculture (Fastest-Growing) In the US Genetic Engineering Market, the end use segment is primarily dominated by pharmaceuticals, owing to the critical need for innovative therapies and advancements in biotechnology. This sector heavily influences market trends and investments, reflecting a robust market share among its components. Agriculture, while currently smaller, exhibits rapid growth due to increasing demands for genetically modified crops and sustainability in farming practices, making it a notable contender in future projections. As we continue to see advancements in genetic engineering, the agricultural sector is expected to surge as more biotech solutions are developed to address food security and climate challenges. Furthermore, the pharmaceuticals segment is stimulated by a greater focus on personalized medicine and biopharmaceutical discoveries, fostering significant growth and investment opportunities. Overall, both segments are pivotal to the evolution of the US Genetic Engineering Market, each pushing the boundaries of innovation and application in distinct ways. Pharmaceuticals (Dominant) vs. Agriculture (Emerging) The pharmaceuticals sector in the US Genetic Engineering Market represents a dominant force, characterized by extensive research and development activities focused on cutting-edge therapies and drug production. With strong regulatory frameworks and collaborations between biotech firms and research institutions, this segment continually pushes for breakthroughs that enhance patient outcomes. Additionally, the demand for biologics and sophisticated gene therapies has propelled investments into this sector, solidifying its position. In contrast, the agriculture segment, while emerging, demonstrates significant potential as it responds to the need for increased crop yields, pest resistance, and climate adaptability. Innovations in genetically modified organisms (GMOs), coupled with consumer interest in sustainable practices, are driving this growth, placing agriculture on a trajectory of rapid expansion in the genetic engineering landscape. ### By Technology: CRISPR (Largest) vs. Gene Therapy (Fastest-Growing) In the US Genetic Engineering Market, the technology segment is marked by diverse innovations, with CRISPR technology leading by a substantial margin. Its unparalleled precision and versatility have positioned it as the largest segment, capturing the attention of various industries. [Gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399), while smaller in comparison, is experiencing rapid advancements, drawing significant investments and research efforts aimed at treating genetic disorders, thereby establishing itself as the fastest-growing segment in the market. Growth in the technology segment is primarily driven by the increasing prevalence of genetic disorders and advancements in biotech research. As researchers continue to uncover the potential of synthetic biology and genetic modifications, applications in healthcare, agriculture, and industrial biotechnology are expected to expand. Increased governmental and private funding for gene-modification technologies further propels this growth, making it a focal point of interest for stakeholders in the US market. Technology: CRISPR (Dominant) vs. Gene Therapy (Emerging) CRISPR technology stands as a dominant force in the US Genetic Engineering Market due to its efficiency in [gene editing](https://www.marketresearchfuture.com/reports/gene-editing-market-707), which allows for targeted alterations in DNA with minimal off-target effects. This revolutionary tool has paved the way for breakthroughs in various sectors, including therapeutic development and agricultural improvements. Conversely, gene therapy represents an emerging segment, showcasing potential through innovative treatments for genetic disorders and cancers. The emergence of adeno-associated viruses (AAVs) and improved delivery mechanisms has enhanced its viability. As both segments evolve, collaboration across industries is likely to stimulate advancements, fostering an environment where CRISPR's foundational techniques support the rapid growth of gene therapies. ### By Research Type: Applied Research (Largest) vs. Clinical Research (Fastest-Growing) In the US Genetic Engineering Market, the research type segment is primarily divided into three major categories: Basic Research, Applied Research, and Clinical Research. Among these, Applied Research holds the largest market share, driven by its practical applications in developing genetic technologies for various industries, including healthcare and agriculture. Basic Research follows, laying the foundational knowledge crucial for advancements, while Clinical Research, although smaller in share, is gaining traction as new therapies and treatments emerge from genetic engineering breakthroughs. Applied Research (Dominant) vs. Clinical Research (Emerging) Applied Research in the US Genetic Engineering Market is characterized by its focus on practical applications that result in innovative solutions across sectors such as pharmaceuticals and biotechnology. It plays a critical role in translating scientific discoveries into real-world applications, leading to advancements in gene editing and biotechnology products. In contrast, Clinical Research is emerging rapidly, propelled by heightened investment in gene therapies and the increasing number of clinical trials. As regulatory landscapes evolve, Clinical Research is expected to grow increasingly relevant, emphasizing patient-centered outcomes and personalized medicine approaches. ## Competitive Benchmarking The Genetic Engineering Market is characterized by a dynamic competitive landscape, driven by innovation, regulatory advancements, and increasing demand for genetically modified organisms (GMOs) in agriculture and healthcare. Key players such as Monsanto (US), DuPont (US), and Bayer (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their strategic positioning. Monsanto (US) focuses on developing high-yield crops, while DuPont (US) emphasizes sustainable agricultural practices. Bayer (US) integrates digital solutions into its operations, enhancing efficiency and product development. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and sustainability. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market structure appears moderately fragmented, with a mix of large corporations and smaller biotech firms. This fragmentation allows for diverse innovation pathways, although the influence of major players remains substantial, shaping market trends and consumer preferences. In December 2025, Bayer (US) announced a partnership with a leading AI firm to enhance its crop protection solutions through predictive analytics. This strategic move is likely to bolster Bayer's competitive edge by enabling more precise targeting of pests and diseases, thereby improving yield outcomes for farmers. The integration of AI into Bayer's operations signifies a broader trend towards digital transformation within the industry. In November 2025, DuPont (US) launched a new line of drought-resistant seeds aimed at addressing climate change challenges. This initiative not only aligns with global sustainability goals but also positions DuPont as a leader in climate-resilient agriculture. The introduction of these seeds could potentially capture a significant market share, appealing to environmentally conscious consumers and farmers alike. In October 2025, Monsanto (US) expanded its research facilities in the Midwest, focusing on gene editing technologies. This expansion is indicative of the company's commitment to innovation and its strategic intent to lead in the development of next-generation crops. By investing in advanced research capabilities, Monsanto aims to enhance its product offerings and respond to the evolving needs of the agricultural sector. As of January 2026, current competitive trends in the Genetic Engineering Market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge. ## Recent News & Developments **January 2022:**Pfizer, a global pharmaceutical and biotechnology company with headquarters in the United States, and Beam Therapeutics, a Massachusetts-based company that was first to create CRISPR editing tools, have agreed to a $300 million, four-year contract. **June 2021:**The biotechnology firm Regeneron Pharmaceuticals, with its headquarters located in New York, and Cambridge-based Intellia Therapeutics, which develops biopharmaceuticals, have jointly disclosed a novel therapy that specifically targets the faulty gene responsible for transthyretin amyloidosis. ## Report Scope | MARKET SIZE 2024 | 403.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 487.68(USD Million) | | MARKET SIZE 2035 | 2700.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.87% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Monsanto (US), DuPont (US), Syngenta (US), Bayer (US), Amgen (US), Genentech (US), Illumina (US), Regeneron Pharmaceuticals (US), Corteva Agriscience (US) | | Segments Covered | Application, End Use, Technology, Research Type | | Key Market Opportunities | Advancements in gene editing technologies drive innovation in the US Genetic Engineering Market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the US Genetic Engineering Market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US Genetic Engineering Market?** A: As of 2024, the US Genetic Engineering Market was valued at 403.2 USD Million. **Q: What is the projected market valuation for the US Genetic Engineering Market by 2035?** A: The market is projected to reach a valuation of 2700.0 USD Million by 2035. **Q: What is the expected CAGR for the US Genetic Engineering Market during the forecast period 2025 - 2035?** A: The expected CAGR for the US Genetic Engineering Market during the forecast period 2025 - 2035 is 18.87%. **Q: Which companies are considered key players in the US Genetic Engineering Market?** A: Key players in the market include Monsanto, DuPont, Syngenta, Bayer, Amgen, Genentech, Illumina, Regeneron Pharmaceuticals, and Corteva Agriscience. **Q: How does the Agricultural Biotechnology segment perform in the US Genetic Engineering Market?** A: The Agricultural Biotechnology segment was valued at 100.0 USD Million in 2024 and is projected to grow to 600.0 USD Million by 2035. **Q: What is the valuation of the Medical Biotechnology segment in the US Genetic Engineering Market?** A: The Medical Biotechnology segment had a valuation of 150.0 USD Million in 2024, with projections reaching 900.0 USD Million by 2035. **Q: What are the projected values for the Industrial Biotechnology segment by 2035?** A: The Industrial Biotechnology segment was valued at 80.0 USD Million in 2024 and is expected to grow to 500.0 USD Million by 2035. **Q: What is the expected growth for the Environmental Biotechnology segment in the US Genetic Engineering Market?** A: The Environmental Biotechnology segment had a valuation of 73.2 USD Million in 2024, with projections indicating growth to 700.0 USD Million by 2035. **Q: Which technology segments are included in the US Genetic Engineering Market analysis?** A: The technology segments include CRISPR, Gene Therapy, Synthetic Biology, and Genetic Modification, with varying valuations from 80.0 to 113.2 USD Million in 2024. **Q: What are the research type segments in the US Genetic Engineering Market?** A: Research type segments include Basic Research, Applied Research, and Clinical Research, with valuations ranging from 80.0 to 173.2 USD Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-genome-editing-engineering-market-21799*